PTGX Protagonist Therapeutics, Inc

BEARISH Impact: 5/10 144
Horizon days Filed May 12, 2026 Processed 28d 5h ago SEC 0001968582-26-000430
Form 144 — notice of proposed sale of securities
Latest settled — T+5d
PTGX ▼ -5.30% at T+5d
SHORT call ✓ call won +5.30% · α vs SPY +4.15% · entry $103.88 → $98.37
Next anchor: T+20d in 9h
Currently $105.87 · -1.92% from $103.88 entry (call sign-flipped)
Entry anchored
May 12, 03:59 PM ET
via Databento tick
T+1d
0.00%
call 0.00% · α -0.00%
$103.88
settled 28d ago
T+5d
-5.30%
call +5.30% · α +4.15%
$98.37
settled 22d ago
T+20d
call — · α —
in 9h
T+60d
call — · α —
in 8w

Price Chart

Loading chart...

Executive Summary

CEO Dinesh Patel filed a Form 144 to sell 75,000 shares (~$7.76M at the filing date) via J.P. Morgan. This is a material insider sale by the CEO, representing about 1.2% of his known holdings and 0.1% of market cap. The sale follows an option exercise and comes amid strong analyst consensus (89% bullish) and a $6.7B market cap.

Actionable Insight

CEO selling $7.76M via Form 144 is a notable insider disposition. While the sale is small relative to market cap, the CEO's intent to sell a meaningful portion of his holdings (1.2% of known position) warrants monitoring. Watch for actual Form 4 filings to confirm execution and any subsequent insider buying patterns.

Key Facts

  • CEO Dinesh Patel filed Form 144 to sell 75,000 shares of common stock.
  • Approximate dollar value of proposed sale: $7,762,500.
  • Shares to be sold via J.P. Morgan Securities LLC.
  • Patel's total beneficial ownership after sale: ~64,311,373 shares.
  • Sale follows an option exercise of 75,000 shares on the same date.
  • Filing date: May 12, 2026.
  • Recent insider activity (30d): 3 sells totaling $4.4M.
  • Market cap: $6.7B; analyst consensus 89% bullish.

Financial Impact

CEO proposes to sell ~$7.76M worth of stock, ~0.12% of market cap.

dilutioninsider holdings

Risk Factors

  • Insider selling by CEO may signal lack of confidence in near-term prospects.
  • Sale is not yet executed; Form 144 is an intent to sell.
  • Option exercise suggests shares were acquired at lower cost, reducing signaling weight.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (19 analysts)

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001968582-26-000430
Document: 0001968582-26-000430-index.html0001968582-26-000430
Document: 0001968582-26-000430.txt0001968582-26-000430
5 reports for PTGX
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for PTGX — sortable, filterable
Type Now
May 12, 2026
28d ago
144
BEARISH ★ 5/10
$103.88 $98.37▲ +5.30%▲ +4.15%$105.87 (−1.92%)
May 8, 2026
4w ago
Insider Cluster
NEUTRAL ★ 4/10
$99.36 $105.55▲ +6.23%▲ +4.77%$105.87 (+6.55%)
May 8, 2026
4w ago
Insider Cluster
NEUTRAL ★ 5/10
$99.36 $105.55▲ +6.23%▲ +4.77%$105.87 (+6.55%)
May 5, 2026
5w ago
8-K
BULLISH ★ 7/10
$103.97 $99.95▼ −3.87%▼ −5.00%$105.87 (+1.83%)
Feb 25, 2026
15w ago
8-K
MIXED ★ 6/10
$87.10 $94.83▲ +8.87%▲ +9.97%$105.87 (+21.55%)
Showing 5 of 5

US Market Status

Market Closed — Opens Thu (10h 57m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access